

# Contents

<b>1 Mineralogy of Asbestos. . . . .</b>	<b>1</b>
Thomas A. Sporn	
1.1 Introduction and Historical Background. . . . .	1
1.2 Geologic and Mineralogic Features . . . . .	2
1.3 Distribution and Physicochemical Properties of Chrysotile . . . . .	4
1.4 Distribution and Physicochemical Properties of the Amphibole Species . . . . .	7
1.5 Identification and Characterization of Asbestos . . . . .	9
References. . . . .	10
<b>2 Epidemiology of Mesothelioma and Historical Background. . . . .</b>	<b>13</b>
J.E. Craighead	
References . . . . .	23
<b>3 Imaging of Mesothelioma . . . . .</b>	<b>27</b>
Ritu R. Gill	
3.1 Introduction . . . . .	27
3.2 Patterns of Presentation and Imaging Features . . . . .	28
3.3 Preoperative Evaluation of MPM. . . . .	29
3.4 Postoperative Evaluation . . . . .	36
3.5 Unresectable Disease . . . . .	36
3.6 Future Directions . . . . .	38
3.7 Summary . . . . .	41
References . . . . .	41
<b>4 Biopsy Techniques for the Diagnosis of Mesothelioma . . . . .</b>	<b>45</b>
J. Walters and Nick A. Maskell	
4.1 Introduction . . . . .	45
4.2 Clinical Presentation . . . . .	46

4.3	Investigation of Pleural Effusion . . . . .	46
4.3.1	Cytology . . . . .	46
4.4	Investigation of Pleural Thickening with No Effusion. . . . .	47
4.5	Percutaneous Pleural Biopsy Techniques . . . . .	47
4.5.1	Abrams Needle . . . . .	47
4.5.2	Radiologically Guided Percutaneous Pleural Biopsy . . . . .	48
4.5.3	Positron Emission Tomography (PET) CT . . . . .	49
4.6	Thoracoscopy . . . . .	49
4.6.1	Local Anaesthetic Thoracoscopy . . . . .	50
4.6.2	Video-Assisted Thoracoscopic Surgery . . . . .	51
4.7	Open Biopsy . . . . .	52
4.8	Prophylactic Radiotherapy . . . . .	52
	References . . . . .	53
<b>5</b>	<b>Pathohistological Diagnosis and Differential Diagnosis . . . . .</b>	<b>57</b>
	Iris Tischoff, Matthias Neid, Volker Neumann, and Andrea Tannapfel	
5.1	Introduction . . . . .	58
5.2	Malignant Mesothelioma of the Pleura . . . . .	58
5.2.1	Morphology . . . . .	58
5.3	Differential Diagnosis of Malignant Mesothelioma and Pleural Metastases . . . . .	61
5.3.1	Morphological Differences . . . . .	61
5.3.2	Immunohistochemistry . . . . .	62
5.4	Reactive Versus Neoplastic Mesothelial Proliferation . . . . .	65
5.5	Primary Pleural Tumours Other than Malignant Mesothelioma . . . . .	66
5.5.1	Peritoneal Mesothelioma . . . . .	67
5.5.2	Malignant Mesothelioma of Tunica Vaginalis Testis . . . . .	69
5.5.3	Well-Differentiated Papillary Mesothelioma . . . . .	69
5.5.4	Prognosis and Predictive Factors . . . . .	70
5.5.5	Differential Diagnosis . . . . .	71
5.5.6	Benign Lesions . . . . .	71
5.5.7	Malignant Lesions . . . . .	72
5.5.8	Immunohistochemistry . . . . .	73
5.6	Primary Peritoneal Carcinoma/Metastases of Serous Ovarian Cancer Versus Malignant Peritoneal Mesothelioma . . . . .	74
	References . . . . .	75
<b>6</b>	<b>Mesothelioma and Analysis of Tissue Fiber Content . . . . .</b>	<b>79</b>
	Volker Neumann, Stefan Löseke, and Andrea Tannapfel	
6.1	Introduction . . . . .	80
6.2	Techniques for Analysis of Pulmonary Mineral-Fiber Content . . . . .	82
6.2.1	Lung Tissue Digests . . . . .	82
6.3	Methods for Mineral Fiber Analysis . . . . .	83
6.3.1	Light Microscopy (LM) . . . . .	83

6.3.2	Electron Microscopy . . . . .	83
6.3.3	Comparability of Results Generated by Light or Electron Microscopy . . . . .	84
6.3.4	Reference Population and Background Lung Asbestos Burden . . . . .	84
6.3.5	Asbestos Bodies and Fiber Counting. . . . .	84
6.4	Asbestos Lung Tissue Content in Patients with Mesothelioma. . . . .	85
6.4.1	Light Microscopy. . . . .	85
6.4.2	Electron Microscopy . . . . .	86
6.4.3	Asbestos Content and Fiber Dimensions in Pleural Samples . . . . .	86
6.5	Discussion . . . . .	87
6.5.1	Asbestos Bodies and Fiber Burden of the Lung . . . . .	87
6.5.2	Latency Period and Mean Age at Diagnosis of Mesothelioma . . . . .	88
6.5.3	Clearance and Biopersistence of Asbestos Fibers . . . . .	88
6.5.4	Carcinogenic Potency of Asbestos Fibers . . . . .	89
6.5.5	Peritoneal Mesothelioma . . . . .	89
6.5.6	Asbestos-Associated Mesothelioma and Other Possible Causes of Malignant Mesothelioma . . . . .	89
6.5.7	Threshold or Cut-off Level . . . . .	90
6.6	Conclusion . . . . .	90
	References . . . . .	90
<b>7</b>	<b>Surgical Therapy of Mesothelioma . . . . .</b>	<b>97</b>
	David Rice	
7.1	Introduction . . . . .	97
7.2	Natural History . . . . .	98
7.3	Diagnosis . . . . .	98
7.3.1	Video-Assisted Thoracoscopy . . . . .	98
7.4	Staging . . . . .	100
7.4.1	Laparoscopy. . . . .	100
7.4.2	Mediastinoscopy . . . . .	101
7.4.3	Thoracoscopy. . . . .	102
7.4.4	Endoscopic Staging . . . . .	102
7.5	Palliative Surgery. . . . .	103
7.5.1	Pleural Drainage . . . . .	103
7.5.2	Pleurectomy . . . . .	103
7.6	Cytoreductive Surgery. . . . .	105
7.6.1	Extrapleural Pneumonectomy (EPP). . . . .	105
7.6.2	Pleurectomy/Decortication (P/D) . . . . .	113
7.6.3	Intrapleural Therapies . . . . .	115
7.6.4	Extrapleural Pneumonectomy Versus Pleurectomy/Decortication . . . . .	119
7.6.5	Does Cytoreductive Surgery Improve Survival? . . . . .	120
7.7	Summary . . . . .	121
	References . . . . .	121

<b>8</b>	<b>Chemotherapy and Radiotherapy for Mesothelioma</b>	<b>127</b>
	Xavier Dhalluin and Arnaud Scherpereel	
8.1	Introduction	127
8.2	Radiotherapy	128
8.2.1	Radical Radiotherapy	128
8.2.2	Prophylactic Radiotherapy	132
8.3	Systemic Therapies for Malignant Pleural Mesothelioma	133
8.3.1	Systemic Chemotherapy	133
8.3.2	Targeted Therapies	138
8.3.3	Immunomodulators, Gene Therapy and Cell Therapy	141
8.4	Conclusion	142
	References	142
<b>9</b>	<b>Genetics and Molecular Biology of Mesothelioma</b>	<b>149</b>
	Dean A. Fennell	
9.1	Apoptosis as a Tumor Suppressor Mechanism	149
9.2	Key Alterations in the Core Apoptosis Signaling in Mesothelioma	149
9.2.1	Regulation of the Intrinsic (Mitochondrial) Apoptosis Pathway in Mesothelioma	149
9.2.2	Extrinsic Apoptosis Pathway Regulation in Mesothelioma	152
9.2.3	Inhibitors of Apoptosis in Mesothelioma	152
9.3	Tumor Suppressor Loss in Mesothelioma	152
9.3.1	Loss of nf2 Is Frequent in Mesothelioma	152
9.3.2	NF2 Encodes the Tumor Suppressor Merlin	153
9.3.3	PLZF Is a Novel Tumor Suppressor in Mesothelioma	154
9.4	Therapeutic Inhibition of Survival Pathways	154
9.4.1	PI3K/AKT/mTOR Axis in Mesothelioma	154
9.4.2	HGF/cMET Pathway Is Activated in Mesothelioma	154
9.4.3	WNT Pathway Activation in Mesothelioma	155
9.4.4	Estrogen Receptor Beta	156
9.5	Therapeutic Reactivation of Tumor Suppressors	156
9.5.1	Epigenomic Dysregulation in Mesothelioma	156
9.5.2	Targeting the Mesothelioma Epigenome via Inhibition of Histone Deacetylases	157
9.5.3	Targeting the Ubiquitin Proteasome Pathway	158
9.6	Synthetic Lethal Strategies	158
9.7	Summary	159
	References	159

<b>10</b>	<b>Early Stages of Mesothelioma, Screening and Biomarkers. . . . .</b>	<b>169</b>
	Sonja Klebe and Douglas W. Henderson	
10.1	Early-Stage Malignant Mesothelioma, Including the Concept of Mesothelioma In Situ and the Distinction from Reactive Mesothelial Hyperplasia . . . . .	169
10.2	Biomarkers for Early-Stage Epithelioid Malignant Mesothelioma Versus Reactive Mesothelial Hyperplasia. . . . .	174
10.2.1	Epithelial Membrane Antigen (EMA) . . . . .	174
10.2.2	GLUT-1. . . . .	175
10.2.3	Bcl-2 . . . . .	176
10.2.4	p53 . . . . .	176
10.2.5	X-Linked Inhibitor of Apoptosis Proteins (XIAP). . . . .	177
10.2.6	P-Glycoprotein (P-170). . . . .	177
10.2.7	Neural Cell Adhesion Molecules (NCAMs): CD56. . . . .	177
10.3	Screening for Malignant Mesothelioma and Prognostic Biomarkers: Serum Levels of Soluble Mesothelin-Related Proteins (SMRPs), Osteopontin (OPN), Megakaryocyte Potentiating Factor (MKPF) and CA125 . . . . .	178
10.3.1	Introductory Remarks on Screening for Malignant Mesothelioma. . . . .	178
10.3.2	Radiological Screening for MM. . . . .	179
10.3.3	Soluble Mesothelin-Related Proteins (SMRPs) . . . . .	179
10.3.4	Serum Osteopontin (OPN) Levels . . . . .	181
10.3.5	Megakaryocyte Potentiating Factor (MKPF) . . . . .	182
10.3.6	CA125. . . . .	182
10.3.7	Summary. . . . .	182
10.4	Aquaporins and Malignant Mesothelioma . . . . .	183
	References. . . . .	185



<http://www.springer.com/978-3-642-10861-7>

Malignant Mesothelioma  
Tannapfel, A. (Ed.)  
2011, XII, 196 p., Hardcover  
ISBN: 978-3-642-10861-7